Effect of Epidermal Growth Factor on Mouse Intestinal Damage from Melphalan
Author Information
Author(s): B.A. Robinson, R.D. Clutterbuck, J.L. Millar, T.J. McElwain
Primary Institution: Institute of Cancer Research; Royal Marsden Hospital
Hypothesis
Does epidermal growth factor (hEGF) protect against intestinal epithelial damage caused by melphalan in mice?
Conclusion
The study found that hEGF did not provide a consistent protective effect against melphalan-induced intestinal damage in mice.
Supporting Evidence
- Administration of hEGF before melphalan reduced jejunal crypt survival.
- Oral administration of hEGF had no effect on melphalan-induced damage.
- Different regimens of hEGF administration were explored but did not yield significant protective effects.
Takeaway
The researchers wanted to see if a growth factor could help mice recover from medicine that hurts their intestines, but it didn't work as they hoped.
Methodology
CBA mice were treated with melphalan and hEGF, and intestinal damage was assessed through various methods including [14C]-xylose uptake and microcolony survival.
Limitations
The study did not explore all possible regimens and timing for hEGF administration.
Participant Demographics
Adult male and female CBA/ca mice, at least 12 weeks old, weighing 20-30g.
Statistical Information
P-Value
p<0.02
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website